PerkinElmer, LinaTech enter oncology technology development and marketing agreement

PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, today announced that it has entered into a joint technology development and marketing agreement with LinaTech, a leading manufacturer of medical devices and software for treating cancer with radiotherapy.

“We are delighted to collaborate with a global leader of PerkinElmer's reputation for quality product development, along with unmatched worldwide reach in imaging. We feel that both companies will strongly complement each other as we work toward better solutions for oncology treatment.”

The intent of the collaboration is to develop, implement, market and distribute imaging technologies for the treatment of certain types of cancer. The products to be developed include cost-effective imaging solutions that allow customers to upgrade their legacy film-based radiotherapy systems, and also include imaging subsystems for sales to radiotherapy system manufacturers. The first generation product, the FDA 510k-approved LinaTech TiGRT Image Viewing System, will be showcased at the American Society of Therapeutic Radiology and Oncology in San Diego next week.

Brian Giambattista, president, Medical Imaging, PerkinElmer, said, "PerkinElmer is very pleased to be working with LinaTech, with its strong track record of successful innovation in radiotherapy solutions and systems. We look forward to very compelling outcomes from our development project, as we seek to create new technologies for the benefit of cancer patients, by giving doctors and hospitals more imaging options."

Jonathan Yao, president of LinaTech, said, "We are delighted to collaborate with a global leader of PerkinElmer's reputation for quality product development, along with unmatched worldwide reach in imaging. We feel that both companies will strongly complement each other as we work toward better solutions for oncology treatment."

SOURCE PerkinElmer, Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    PerkinElmer. (2019, April 30). PerkinElmer, LinaTech enter oncology technology development and marketing agreement. News-Medical. Retrieved on August 18, 2019 from https://www.news-medical.net/news/20101029/PerkinElmer-LinaTech-enter-oncology-technology-development-and-marketing-agreement.aspx.

  • MLA

    PerkinElmer. "PerkinElmer, LinaTech enter oncology technology development and marketing agreement". News-Medical. 18 August 2019. <https://www.news-medical.net/news/20101029/PerkinElmer-LinaTech-enter-oncology-technology-development-and-marketing-agreement.aspx>.

  • Chicago

    PerkinElmer. "PerkinElmer, LinaTech enter oncology technology development and marketing agreement". News-Medical. https://www.news-medical.net/news/20101029/PerkinElmer-LinaTech-enter-oncology-technology-development-and-marketing-agreement.aspx. (accessed August 18, 2019).

  • Harvard

    PerkinElmer. 2019. PerkinElmer, LinaTech enter oncology technology development and marketing agreement. News-Medical, viewed 18 August 2019, https://www.news-medical.net/news/20101029/PerkinElmer-LinaTech-enter-oncology-technology-development-and-marketing-agreement.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
New PerkinElmer assay kits use AlphaLISA technology for biotherapeutic drug development